With a goal of expanding its presence in the global molecular diagnostics market, Seegene Inc, Seoul, Republic of Korea, has opened a new subsidiary, Seegene Technologies Inc, in Concord, Calif.
In addition to expanding its client base, Seegene Technologies will continue to develop multiplex reagents for respiratory and gastrointestinal infections that enable simultaneous multiple detection and quantification of various types of pathogens in a single test. In February, Seegene received its first 510(k) market clearance for its tagging oligonucleotide capture and extension (TOCE) -based assay for herpes simplex virus types 1 and 2.
The company also announced plans to establish a US-based manufacturing and supply system by 2017 and hopes to build partnerships with global in vitro diagnostics companies in order to develop mid- to long-term growth drivers.
Jong-Yoon Chun, PhD, founder, chief executive, and chief technology officer of Seegene
“We are very pleased to establish Seegene Technologies, which is an important building block in supporting Seegene’s strong and growing global market presence,” says Jong-Yoon Chun, PhD, founder, chief executive, and chief technology officer of Seegene. “With the perfection of real-time polymerase chain reaction technologies achieved in our technology portfolio of TOCEvh and multiple detection temperatures (MuDT) technologies, we will concentrate all our efforts to achieve commercial success in the global molecular diagnostics market.”
For more information, visit Seegene.
